Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 20 mg, lactosum monohydricum 27 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.14 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 0.67 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 50 mg, lactosum monohydricum 67.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.36 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.68 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 70 mg, lactosum monohydricum 94.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.5 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 2.35 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 80 mg, lactosum monohydricum 108 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.58 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 2.69 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 100 mg, lactosum monohydricum 135 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.72 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 3.36 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - compresse rivestite con film - dasatinibum 140 mg, lactosum monohydricum 189 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.72 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 4.7 mg, e 171, triacetinum, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika

União Europeia - italiano - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agenti antineoplastici - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

União Europeia - italiano - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agenti antineoplastici - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

União Europeia - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Suíça - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - nilotinibum - capsule - nilotinibum 200 mg ut nilotinibi hydrochloridum monohydricum, lactosum monohydricum 156.11 mg, crospovidonum, poloxamerum 188, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, e 172 (rubrum), pro capsula. - trattamento della leucemia mieloide cronica - synthetika